ASH 2024 Summary: Myeloma Highlights and Impact on Practice

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Find latest Myeloma videos · 500+ videos

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

10 seconds

Playback speed

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

This video is featured in the 2024 ASH Annual Meeting Insights Hub

ASH 2024 Summary: Myeloma Highlights and Impact on Practice

By 2024 ASH Annual Meeting Insights Hub FEATURING Hamza Hashmi

1,249 views

January 9, 2025

Comments 0

Insights on Proteasome Inhibitor Combinations at First Relapse in Mu…

Feat. M. Levy

2024 ASH Annual Meeting Insights Hub: Myeloma Videos

New

ASH 2024 Insights: Upfront Use of Anti-CD38 Monoclonal Antibodies in…

2024 ASH Annual Meeting Insights Hub

A. Khan

61 views

ASH 2024 Insights: Association of Pre-Treatment Biomarkers With Toxi…

2024 ASH Annual Meeting Insights Hub

D. Hansen

40 views

ASH 2024 Insights: Belamaf Monotherapy in Pts With R/R Light Chain A…

2024 ASH Annual Meeting Insights Hub

E. Kastritis

36 views

View All

FDA Approval of Isatuximab in 1L MM: Perspectives for Practice

Dana-Farber Cancer Institute

P. Richardson

964 views

ASH 2024 Review: Key Multiple Myeloma Abstracts

Cleveland Clinic Taussig Cancer Institute

N. Callander

419 views

ASH 2024 Summary: Multiple Myeloma Highlights and Clinical Implicati…

2024 ASH Annual Meeting Insights Hub

S. Al Hadidi

451 views

ASH 2024 Insights: Dara vs. Len Maintenance in NDMM - Interim Result…

2024 ASH Annual Meeting Insights Hub

U. Shah

229 views

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

4.8K views

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Banerjee

788 views

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

366 views

Debate: Using BCMA CAR-T in Early vs Late Line R/R MM Treatment

Louisville Hematology Highlights

K. Patel, S. Usmani

176 views

ASH 2024 Summary: Transplant in Myeloma - Key Factors in Decision-Ma…

2024 ASH Annual Meeting Insights Hub

A. Perrot

178 views

Real-World Characteristics and Outcomes in Patients With RRMM Receiv…

Adeel Khan

138 views

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

485 views

ASH 2024 Summary: Highlights in AL Amyloidosis and SMM

2024 ASH Annual Meeting Insights Hub

S. Al Hadidi

189 views

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

587 views

CAR-T Strategies and Clinical Considerations for R/R MM

Moffitt Cancer Center

K. Patel

148 views

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

284 views

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Indy Hematology Review

K. Anderson

1.3K views

Making Sense in R/R Myeloma: Guideline-Based Current Approaches

Saurabh Chhabra

174 views

New

The Future of NDMM Treatment: Ongoing Trials and Key ASH 2024 Oral A…

University of Miami Sylvester Comprehensive Cancer Center

O. Landgren

96 views

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

727 views

Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

M. Kwok

484 views

AUTOPLAY

Login

Login

Join VuMedi

ASH 2024 Summary: Myeloma Highlights and Impact on Practice

Insights on Proteasome Inhibitor Combinations at First Relapse in Mu…

2024 ASH Annual Meeting Insights Hub: Myeloma Videos

ASH 2024 Insights: Upfront Use of Anti-CD38 Monoclonal Antibodies in…

ASH 2024 Insights: Association of Pre-Treatment Biomarkers With Toxi…

ASH 2024 Insights: Belamaf Monotherapy in Pts With R/R Light Chain A…

Related Videos

FDA Approval of Isatuximab in 1L MM: Perspectives for Practice

ASH 2024 Review: Key Multiple Myeloma Abstracts

ASH 2024 Summary: Multiple Myeloma Highlights and Clinical Implicati…

ASH 2024 Insights: Dara vs. Len Maintenance in NDMM - Interim Result…

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Multiple Myeloma: Not as Simple as "CRAB" Anymore

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Debate: Using BCMA CAR-T in Early vs Late Line R/R MM Treatment

ASH 2024 Summary: Transplant in Myeloma - Key Factors in Decision-Ma…

Real-World Characteristics and Outcomes in Patients With RRMM Receiv…

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

ASH 2024 Summary: Highlights in AL Amyloidosis and SMM

ESMO 2024 Summary: Highlights in Heme Malignancies

CAR-T Strategies and Clinical Considerations for R/R MM

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

2024 Updates on Emerging & Current Treatment of Multiple Myeloma

Making Sense in R/R Myeloma: Guideline-Based Current Approaches

The Future of NDMM Treatment: Ongoing Trials and Key ASH 2024 Oral A…

Advances in Multiple Myeloma 2024: From Bench to Bedside

Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma